Based on these promising results, a phase Ib/II study evaluating VS-6766 with or without defactinib for the treatment of KRAS (especially G12V subtype) +, advanced, NSCLC (NCT04620330) was initiated in December 2020 and is currently recruiting patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.